In the European Union in 2012, more than 447,000 individuals were diagnosed with colorectal cancer (CRC). About 65% of all new cases occur in high-income countries, and behavioural risk factors (such as diet, alcohol intake, and physical inactivity) are suspected to be involved.
In Europe, CRC is the second most common cause of cancer death in both men and women. It is the second most commonly occurring cancer in women, after breast cancer, and the third most common in men, after lung and prostate cancer.
In 2016, colorectal cancer in the Norwegian population of 5 million people added up to over 4,300 newly diagnosed cases, making it one of the most prevalent cancers in Norway today. In total, almost 24,000 people in Norway are living with CRC every day (Kreftregistreret). There is expected to be a steady increase in CRC incidence, largely because of the ageing population. The management of the disease is multidisciplinary, involving precision diagnostics in radiology and pathology, and highly specialised knowledge in oncology and surgery. Recognising the high incidence rates and the therapeutic complexities, the impact of CRC on health services, nationally as well as globally, is significant. As new research emerges, it is critical that health care professionals are able to rapidly bridge the gap between science and clinical care of patients. The Acredit Network seeks to bridge this gap through a comprehensive clinical and translational research program.
(Read more about the disease (in Norwegian) at: http://www.oncolex.no/no/Tykktarm.aspx)